ARO-ENaC

ENaC inhibitor (epithelial sodium channel) · Arrowhead Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARO-ENaC, covering 2025-12-17 to 2025-12-17. Get the full timeline:

Most recent: Clinical Trial Update: Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis [Phase 1, Phase 2]